Immunology
4 drugs are in development for Thyroid Eye Disease.
- Companies
- 3
- Clinical trials
- 20
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Thyroid Eye Disease pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| tepezza | Horizon Therapeutics Public Ltd Co (HZNP) |
Phase 3(2)
| Drug | Company |
|---|---|
| veligrotug | Viridian Therapeutics, Inc.\DE (VRDN) |
| VRDN-001 | Viridian Therapeutics, Inc.\DE (VRDN) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| lonigutamab | ACELYRIN, Inc. (SLRN) |
About this indication
Thyroid Eye Disease context
Immunology·MeSH: Graves Ophthalmopathy (D049970)
Also known as: Disease, Graves Eye, Dysthyroid Ophthalmopathies, Ophthalmopathy, Dysthyroid, Ophthalmopathy, Graves, Ophthalmopathy, Thyroid Associated, Orbitopathy, Graves, Thyroid Associated Ophthalmopathies, Thyroid Eye Diseases
Prevalence
5581.4 / 100K
Incidence
918.7 / 100K/yr
Frequently asked questions
How many drugs are in development for Thyroid Eye Disease?
BioSniper tracks 4 drugs in development for Thyroid Eye Disease across 3 companies.
How many clinical trials target Thyroid Eye Disease?
There are 20 clinical trials targeting Thyroid Eye Disease tracked by BioSniper.
What is the prevalence of Thyroid Eye Disease?
The estimated prevalence of Thyroid Eye Disease is approximately 5581.4 per 100,000 population.